Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]
News [3223]
Articles [134]
Editorials [3]
Conferences [121]
elearning [18]
Ibrutinib induces responses in aggressive lymphomas
Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA
Ibrutinib induces responses in aggressive lymphomas ( Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA )
13 Apr 2012
Recent advances in multiple myeloma therapy
Prof San Miguel, Prof Philippe Moreau, Prof Antonio Palumbo, Prof Meletios...
Recent advances in multiple myeloma therapy ( Prof San Miguel, Prof Philippe Moreau, Prof Antonio Palumbo, Prof Meletios Dimopoulos and Prof Thierry Facon )
14 Feb 2012
Recent advances in non-Hodgkin’s lymphoma therapy
Prof Mathias Rummel, Prof Umberto Vitolo, Prof Georg Hess, Prof Finbarr Cotter
Recent advances in non-Hodgkin’s lymphoma therapy ( Prof Mathias Rummel, Prof Umberto Vitolo, Prof Georg Hess, Prof Finbarr Cotter )
14 Feb 2012
BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory...
Prof Susan O’Brien - University of Texas MD Anderson Cancer Center, Houston
BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma ( Prof Susan O’Brien - University of Texas MD Anderson Cancer Center, Houston )
9 Jan 2012
Obinutuzumab with rituximab in patients with relapsed CD20 and indolent B-Cell...
Dr Laurie Sehn - University of British Columbia, Vancouver, Canada
Obinutuzumab with rituximab in patients with relapsed CD20 and indolent B-Cell non-hodgkin lymphoma (GAUSS) ( Dr Laurie Sehn - University of British Columbia, Vancouver, Canada )
9 Jan 2012
ABVD chemo with radiation therapy for limited-stage hodgkin lymphoma
Dr Ralph Meyer - National Cancer Institute of Canada Clinical Trials Group
ABVD chemo with radiation therapy for limited-stage hodgkin lymphoma ( Dr Ralph Meyer - National Cancer Institute of Canada Clinical Trials Group )
9 Jan 2012
Two rituximab dosing strategies for low tumour burden follicular lymphoma...
Prof Brad Kahl - University of Wisconsin, Madison, USA
Two rituximab dosing strategies for low tumour burden follicular lymphoma (RESORT) ( Prof Brad Kahl - University of Wisconsin, Madison, USA )
9 Jan 2012
Cereblon expression required for anti-myeloma activity of lenalidomide and...
Prof Keith Stewart - Mayo Clinic, Scottsdale, USA
Cereblon expression required for anti-myeloma activity of lenalidomide and pomalidomide ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )
9 Jan 2012
The latest for Multiple Myeloma
Prof Paul Richardson - Dana Farber Institute, Boston, USA
The latest for Multiple Myeloma ( Prof Paul Richardson - Dana Farber Institute, Boston, USA )
19 Dec 2011
Myelodysplastic syndrome drug development and combination therapy
Prof Valeria Santini – University of Florence, Italy
Myelodysplastic syndrome drug development and combination therapy ( Prof Valeria Santini – University of Florence, Italy )
19 Dec 2011
Clinical trial data on treatment of chronic lymphocytic leukaemia with PCI...
Dr Susan O’Brien – MD Anderson Cancer Center, Houston, USA
Clinical trial data on treatment of chronic lymphocytic leukaemia with PCI-32765 ( Dr Susan O’Brien – MD Anderson Cancer Center, Houston, USA )
19 Dec 2011
Update and new perspectives in the management of MDS
Dr Mikkael Sekeres – Cleveland Clinic Taussig Institute, USA
Update and new perspectives in the management of MDS ( Dr Mikkael Sekeres – Cleveland Clinic Taussig Institute, USA )
19 Dec 2011

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation